Age, Ki-67, Nodal pCR and overall survival following Neoadjuvant Chemotherapy for Node Positive ER+/Her2-Breast Cancer

被引：0
|
作者：
Moldoveanu, Dan
Goetz, Matthew P.
Hoskin, Tanya L.
Day, Courtney N.
Boughey, Judy C.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P6-01-22
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-01-22
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2-breast cancer
    Moldoveanu, Dan
    Hoskin, Tanya L.
    Day, Courtney N.
    Schulze, Amy K.
    Goetz, Matthew P.
    Boughey, Judy C.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (03) : 419 - 428
  • [2] Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2- breast cancer
    Dan Moldoveanu
    Tanya L. Hoskin
    Courtney N. Day
    Amy K. Schulze
    Matthew P. Goetz
    Judy C. Boughey
    [J]. Breast Cancer Research and Treatment, 2024, 203 : 419 - 428
  • [3] Age, Ki-67, Nodal Pathological Complete response and Overall Survival Following Neoadjuvant Chemotherapy for Node Positive Estrogen Receptor Positive, Her2 Negative Breast Cancer
    Moldoveanu, Dan
    Schulze, Amy
    Goetz, Matthew
    Hoskin, Tanya
    Day, Courtney
    Boughey, Judy C.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S96 - S96
  • [4] Ki67 Gene Expression Was Associated with Complete Response to Neoadjuvant Chemotherapy but with Worse Survival in ER+/HER2Breast Cancer
    Chida, Kohei
    Wu, Rongrong
    Roy, Arya Mariam.
    Yan, Li
    Ishikawa, Takashi
    Hakamada, Kenichi
    Takabe, Kazuaki
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S91 - S91
  • [5] Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
    Burcombe, RJ
    Makris, A
    Richman, PI
    Daley, FM
    Noble, S
    Pittam, M
    Wright, D
    Allen, SA
    Dove, J
    Wilson, GD
    [J]. BRITISH JOURNAL OF CANCER, 2005, 92 (01) : 147 - 155
  • [6] Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
    R J Burcombe
    A Makris
    P I Richman
    F M Daley
    S Noble
    M Pittam
    D Wright
    S A Allen
    J Dove
    G D Wilson
    [J]. British Journal of Cancer, 2005, 92 : 147 - 155
  • [7] Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2-Breast Cancer: Impact of Tumor Ki67 and ER Status
    Akdag, Goncagul
    Yildirim, Sedat
    Dogan, Akif
    Yasar, Zeynep Yuksel
    Bal, Hamit
    Kinikoglu, Oguzcan
    Oksuz, Sila
    Ozkerim, Ugur
    Tunbekici, Salih
    Yildiz, Hacer Sahika
    Turkoglu, Ezgi
    Alan, Ozkan
    Kokten, Sermin Coban
    Isik, Deniz
    Sever, Ozlem Nuray
    Odabas, Hatice
    Yildirim, Mahmut Emre
    Turan, Nedim
    [J]. CHEMOTHERAPY, 2024, 69 (03) : 141 - 149
  • [8] Genomic characterization and oncology outcomes of a locally advanced ER+/HER2-breast cancer cohort treated with neoadjuvant chemotherapy
    Abreu, Maira
    Furlan, Larissa
    Ma, Yutong
    Chen, Hanlin
    Ferreira, Carla
    Fares, Aline
    Constantino, Eduardo
    Nora, Gustavo R.
    Lucio, Gabriela
    Colombo, Tatiana
    Liu, Rui
    Wu, Xue
    Ou, Qiuxiang
    Araujo, Daniel V.
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [9] Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer
    Lee, J.
    Im, Y. H.
    Lee, S. H.
    Cho, E. Y.
    Choi, Y. L.
    Ko, Y. H.
    Kim, J. H.
    Nam, S. J.
    Kim, H. J.
    Ahn, J. S.
    Park, Y. S.
    Lim, H. Y.
    Han, B. K.
    Yang, J. H.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (04) : 569 - 577
  • [10] Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer
    J. Lee
    Y. H. Im
    S. H. Lee
    E. Y. Cho
    Y. L. Choi
    Y. H. Ko
    J. H. Kim
    S. J. Nam
    H. J. Kim
    J. S. Ahn
    Y. S. Park
    H. Y. Lim
    B. K. Han
    J. H. Yang
    [J]. Cancer Chemotherapy and Pharmacology, 2008, 61 : 569 - 577
12345